Unity Biotechnology Future Growth

Future criteria checks 3/6

Unity Biotechnology is forecast to grow earnings and revenue by 55.2% and 68.3% per annum respectively. EPS is expected to grow by 54.3% per annum. Return on equity is forecast to be -61.2% in 3 years.

Key information

55.2%

Earnings growth rate

54.3%

EPS growth rate

Biotechs earnings growth	42.4%
Revenue growth rate	68.3%
Future return on equity	-61.2%
Analyst coverage	Low
Last updated	15 Aug 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:9U9 - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	26	-13	N/A	N/A	2
12/31/2025	N/A	-32	N/A	N/A	2
12/31/2024	N/A	-25	N/A	N/A	2
9/30/2024	N/A	-22	-23	-23	N/A
6/30/2024	N/A	-30	-24	-24	N/A
3/31/2024	N/A	-40	-31	-31	N/A
12/31/2023	N/A	-40	-37	-37	N/A
9/30/2023	N/A	-34	-41	-41	N/A
6/30/2023	N/A	-33	-45	-45	N/A
3/31/2023	0	-31	-49	-49	N/A
12/31/2022	0	-44	-53	-52	N/A
9/30/2022	5	-56	-46	-46	N/A
6/30/2022	5	-59	-47	-46	N/A
3/31/2022	5	-64	-45	-45	N/A
12/31/2021	5	-61	-45	-45	N/A
9/30/2021	N/A	-70	-57	-57	N/A
6/30/2021	N/A	-81	-63	-62	N/A
3/31/2021	N/A	-82	-69	-68	N/A
12/31/2020	N/A	-94	-79	-78	N/A
9/30/2020	N/A	-92	-78	-77	N/A
6/30/2020	N/A	-86	-78	-77	N/A
3/31/2020	N/A	-91	-78	-77	N/A
12/31/2019	N/A	-82	-74	-72	N/A
9/30/2019	N/A	-86	-71	-70	N/A
6/30/2019	N/A	-83	-68	-67	N/A
3/31/2019	N/A	-79	-67	-65	N/A
12/31/2018	N/A	-76	-58	-57	N/A
9/30/2018	1	-67	-57	-55	N/A
6/30/2018	1	-60	N/A	-51	N/A
3/31/2018	1	-52	N/A	-42	N/A
12/31/2017	1	-45	N/A	-38	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 9U9 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1%).

Earnings vs Market: 9U9 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 9U9 is expected to become profitable in the next 3 years.

Revenue vs Market: 9U9 is forecast to have no revenue next year.

High Growth Revenue: 9U9 is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 9U9 is forecast to be unprofitable in 3 years.

Unity Biotechnology Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

Recent updates

New minor risk - Share price stability

UNITY Biotechnology, Inc. Announces the Appointment of Alicia Tozier as Chief Strategy Officer

Insufficient new directors

Unity Biotechnology, Inc., Annual General Meeting, Jun 21, 2024

Unity Biotechnology, Inc. Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME

Unity Biotechnology, Inc. announced delayed annual 10-K filing

Unity Biotechnology, Inc. Announces New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-Lasting, Disease-Modifying Intervention in Vision Loss

Insufficient new directors

Unity Biotechnology, Inc. Doses First Patients in Phase 2 Aspire Study of Ubx1325 in DME

New major risk - Financial position

UNITY Biotechnology, Inc. Announces 48-Week Results from Phase 2 Envision Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration

New major risk - Revenue and earnings growth

Unity Biotechnology, Inc. Announces Design of Phase 2B Aspire Study Evaluating Ubx1325 in Diabetic Macular Edema (Dme)

Unity Biotechnology, Inc. Announces Positive 24-Week Data from Phase 2 Behold Study of UBX1325 in Patients with Diabetic Macular Edema

Unity Biotechnology, Inc. Completes Enrollment in Phase 2 Envision Study of UBX1325 in Wet Age-Related Macular Degeneration

Unity Biotechnology, Inc. has completed a Follow-on Equity Offering in the amount of $45 million.

Unity Biotechnology Announces Positive Data in Phase 2 Behold Study of Ubx1325 in Patients with Diabetic Macular Edema

Unity Biotechnology Receives Non-Compliance Notice from Nasdaq

Unity Biotechnology Receives Non-Compliance Notice from Nasdaq

UNITY Biotechnology Announces Board Changes

UNITY Biotechnology Presentations at ARVO 2022 Showcase UBX1325 as an Investigational Novel Therapeutic Modality for Retinal Vascular Diseases

Unity Biotechnology, Inc., Annual General Meeting, Jun 24, 2022

UNITY Biotechnology Doses First Patient in ENVISION, the Phase 2 Study of UBX1325 in Wet Age-Related Macular Degenera

Unity Biotechnology Completes Enrollment in BEHOLD, the Phase 2 Study of Senolytic Candidate UBX1325 in Diabetic Macular Edema

Kristina Burow Resigns as Member of the Board and All of the Committees of the Board from Unity Biotechnology, Inc

Unity Biotechnology Announces Additional Data from Phase 1 Study of UBX1325 in Advanced Vascular Eye Disease

Unity Biotechnology, Inc. Announces the Design for Its Phase 2 Study of Ubx1325 in Wet Age-Related Macular Degeneration and Anticipated Milestones for 2022

Unity Biotechnology, Inc.(NasdaqGS:UBX) dropped from Russell 3000E Index

UNITY Biotechnology Presents UBX1325 Data Demonstrating Improvement in Retinal Vasculature and Function in Preclinical Models of Diabetic Retinopathy Eye Diseases

Unity Biotechnology, Inc. Announces Impairment of Long Lived Assets for the Three Months Ended December 31, 2020

Unity Biotechnology, Inc. Appoints Alexander Nguyen as General Counsel

Unity Biotechnology, Inc. Announces New Preclinical Research That Reveals A Novel Mechanism for Treating Age-Related Eye Diseases

New 90-day high: €6.20

Unity Biotechnology, Inc. Appoints Przemyslaw (Mike) Sapieha as Chief Scientific Advisor

New 90-day high: €5.29

Unity Biotechnology Announces Executive Changes

New 90-day high: €4.03

Biotechnology Announces First Patient Dosed in Phase 1 Study of UBX1325 in Diabetic Macular Edema

New 90-day low - €2.48

New 90-day high - €10.22

Unity Biotechnology, Inc. announced that it expects to receive $80 million in funding from Hercules Capital, Inc.

Unity Biotechnology, Inc. to Report Q2, 2020 Results on Jul 31, 2020

Unity Biotechnology, Inc.(NasdaqGS:UBX) dropped from Russell Microcap Value Index

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies